Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OrigAMI-2: Amivantamab + chemotherapy vs cetuximab + chemotherapy in first-line left-sided metastatic colorectal cancer
jRCT2031240455Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing Amivantamab + chemotherapy with Erbitux + chemotherapy (2 arms). Primary endpoint: Progression-Free Survival (PFS) by BICR. Started Jan 2025; status: recruiting.
02
Drugs
amivantamabcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031240455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240455.